Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–13 of 13 results
Advanced filters: Author: Joseph Lewnard Clear advanced filters

  • The authors analysed a cohort of men who have sex with men for diagnosed and asymptomatic mpox and report that only 1 in 33 infections is captured by clinical testing. The results indicate that there may be extensive under-reporting and under-diagnosis of mpox.

    • Joseph A. Lewnard
    • Miguel I. Paredes
    • Sara Y. Tartof
    ResearchOpen Access
    Nature Communications
    Volume: 17, P: 1-18

  • Doxycycline post-exposure prophylaxis is recommended in the United States for populations at risk of bacterial sexually transmitted infections, but there is concern about development of antimicrobial resistance. Here, the authors use insurance claims data to estimate the potential impacts of the policy on antimicrobial consumption.

    • Anna M. Parker
    • Jennifer J. Chang
    • Katia J. Bruxvoort
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-13

  • Using a statistical model that incorporates transmission intensity and stratum-specific rates of severe outcomes, either associated with disease or vaccination, a framework is proposed to compare the risks and benefits of deploying new vaccines, using early epidemiological data.

    • Bethan Cracknell Daniels
    • Timothy Endy
    • Henrik Salje
    ResearchOpen Access
    Nature Health
    Volume: 1, P: 120-128

  • Vaccines and infection-acquired immunity reduce infection risk to close contacts through ‘indirect protection’. Here, the authors characterise the strength and durability of vaccine- and infection-acquired indirect protection against SARS-CoV-2 using surveillance data from residents of state prisons in California.

    • Sophia T. Tan
    • Isabel Rodríguez-Barraquer
    • Nathan C. Lo
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-10

  • The SARS-CoV-2 JN.1 lineage spread rapidly in winter 2023-24 with high estimated levels of transmission but limited increase in severe disease burden. Here, the authors use electronic health record data from the United States to investigate the immune history and clinical outcomes of patients infected with this strain.

    • Joseph A. Lewnard
    • Parag Mahale
    • Sara Y. Tartof
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-12

  • The SARS-CoV-2 Omicron lineage XBB/XBB.1.5 became the leading cause of new infections in the US in January 2023. Here, the authors use testing and hospitalisation data and show that this variant has increased ability to evade infection-derived immunity but enhanced vaccine sensitivity.

    • Joseph A. Lewnard
    • Vennis Hong
    • Sara Y. Tartof
    ResearchOpen Access
    Nature Communications
    Volume: 14, P: 1-10

  • Millions of excess deaths are estimated to have occurred in India during the COVID-19 pandemic, but their causes are not well documented at the national level. In this study, the authors use death registration records to describe the extent and causes of excess deaths in the large urban municipality of Madurai.

    • Joseph A. Lewnard
    • Chandra Mohan B
    • Ramanan Laxminarayan
    ResearchOpen Access
    Nature Communications
    Volume: 14, P: 1-14

  • Continuous monitoring of SARS-CoV-2 variant properties is important for public health planning. Here, the authors use data from the United States and show that Omicron BA.4/5 subvariants, which became dominant in mid-2022, have stronger immune escape properties, but are no more severe, than the previously dominant BA.2.

    • Joseph A. Lewnard
    • Vennis Hong
    • Sara Y. Tartof
    ResearchOpen Access
    Nature Communications
    Volume: 14, P: 1-11

  • Pneumococcal and rotavirus vaccines have reduced antibiotic consumption substantially among children under five years old in low- and middle-income countries; however, this effect could be doubled if all countries were to implement vaccination programmes and meet universal vaccine coverage targets.

    • Joseph A. Lewnard
    • Nathan C. Lo
    • Ramanan Laxminarayan
    ResearchOpen Access
    Nature
    Volume: 581, P: 94-99

  • Vaccines preventing tuberculosis disease progression have shown promising results in recent trials. Here, the authors use mathematical modelling to estimate that this type of vaccine could avert 10% of cases of rifampicin-resistant tuberculosis and 7% of deaths from 2020-2035.

    • Han Fu
    • Joseph A. Lewnard
    • Nimalan Arinaminpathy
    ResearchOpen Access
    Nature Communications
    Volume: 12, P: 1-9

  • Comparison of outcomes of SARS-CoV-2 Delta and Omicron infections shows reduced severity of Omicron infections, most notably in unvaccinated individuals, and no differential risk of severe outcomes between subvariants BA.1 and BA.2. The findings highlight the importance of continual assessment of clinical outcomes associated with SARS-CoV-2 variants of concern to inform both medical interventions and healthcare resource management.

    • Joseph A. Lewnard
    • Vennis X. Hong
    • Sara Y. Tartof
    Research
    Nature Medicine
    Volume: 28, P: 1933-1943